BI 456906, GLP-1/glucagon dual agonist. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.
These are long-acting and reach steady state over weeks, so a single day’s timing has little effect. Consistency matters more than the hour.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–4 | 0.6 mg | once weekly | 0.12 mL | 12 u | 4 | 2.4 mg |
| Weeks 5–8 | 1.2 mg | once weekly | 0.24 mL | 24 u | 4 | 4.8 mg |
| Weeks 9–12 | 2.4 mg | once weekly | 0.48 mL | 48 u | 4 | 9.6 mg |
| Weeks 13–16 | 3.6 mg | once weekly | 0.72 mL | 72 u | 4 | 14.4 mg |
| Week 17 onward per 4 weeks from here on |
6 mg | once weekly | 1.2 mL | 120 u ⚠ | 4 | 24 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Initiation | 0.6 mg | once weekly | 0.12 mL | 12 u | 16 doses |
| Step | 2.4 mg | once weekly | 0.48 mL | 48 u | 4 doses |
| Step | 3.6 mg | once weekly | 0.72 mL | 72 u | 2 doses |
| Trial max | 6 mg | once weekly | 1.2 mL | 120 u ⚠ | 1 doses |
A dual GLP-1/glucagon receptor agonist in phase 3, with notable phase 2 results in MASH as well as obesity.
Buy SurvodutidePaid affiliate links.
Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for Survodutide run from 0.6 mg to 6 mg, typically once weekly.6 mg to 6 mg, typically once weekly.6 mg to 6 mg, typically once weekly. This site lists each figure with the source it came from rather than giving a single recommended number.
At 5 mg/mL, a 0.6 mg dose is 12 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 16 doses.
Survodutide is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
Yes — Phase 2 escalation. The week-by-week table on this page converts each step into the exact amount to draw for your mix.
Compounds in the same class, or browse the full catalogue.
A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. D…
Every compound compared in one table: dose range, how often, half-life and evidence tier.
Need this on one page to print, screenshot or send?
Make a dose card →